Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults
The Journal of Infectious Diseases · 15.11.2024 · 230 (5) · e996-e1006
DOI: 10.1093/infdis/jiae316 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 18.06.2024. Verfasst von Jaya Goswami und 26 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease, Research and Development, Moderna, Inc., Cambridge, Massachusetts. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
The mRNA-1345 vaccine demonstrated efficacy against respiratory syncytial virus (RSV) disease with acceptable safety in adults aged ≥60 years in the ConquerRSV trial. Here, humoral immunogenicity results from the trial are presented.
Methods
This phase 2/3 trial randomly assigned adults (≥60 years) to mRNA-1345 50-µg encoding prefusion F (preF) glycoprotein (n = 17 793) vaccine or placebo (n = 17 748). RSV-A and RSV-B neutralizing antibody (nAb) and preF binding antibody (bAb) levels at baseline and day 29 postvaccination were assessed in a per-protocol immunogenicity subset (PPIS; mRNA-1345, n = 1515; placebo, n = 333).
Results
Day 29 nAb geometric mean titers (GMTs) increased 8.4-fold against RSV-A and 5.1-fold against RSV-B from baseline. Seroresponses (4-fold rise from baseline) in the mRNA-1345 groups were 74.2% and 56.5% for RSV-A and RSV-B, respectively. Baseline GMTs were lower among participants who met the seroresponse criteria than those who did not. mRNA-1345 induced preF bAbs at day 29, with a pattern similar to nAbs. Day 29 antibody responses across demographic and risk subgroups were generally consistent with the overall PPIS. Conclusions mRNA-1345 enhanced RSV-A and RSV-B nAbs and preF bAbs in adults (≥60 years) across various subgroups, including those at risk for severe disease, consistent with its demonstrated efficacy in the prevention of RSV disease. Clinical Trials Registration NCT05127434.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Disease, Research and Development, Moderna, Inc., Cambridge, Massachusetts.
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
- Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich.
- Consultorios Médicos Dr. Doreski, Buenos Aires, Argentina.
- Spotlight Research Center, Miami, Florida.
- Department of International Health, Johns Hopkins University, Zakiganj, Sylhet, Bangladesh.
ORCID-Profile: Mugen Ujiie
Förderung
- Moderna, Inc
Zitieren
APA
Goswami, J., Baqui, A. H., Doreski, P. A., Perez Marc, G., Jimenez, G., Ahmed, S., Zaman, K., Duncan, C. J. A., Ujiie, M., Rämet, M., Pérez-Breva, L., Lan, L., Du, J., Kapoor, A., Mehta, S., Tomassini, J. E., Huang, W., Zhou, H., Stoszek, S. K., …, & Das, R. (2024). Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults. The Journal of Infectious Diseases, 230(5), e996-e1006. https://doi.org/10.1093/infdis/jiae316
Vancouver
Goswami J, Baqui AH, Doreski PA, Perez Marc G, Jimenez G, Ahmed S, et al. Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults. The Journal of Infectious Diseases. 2024;230(5):e996-e1006. doi:10.1093/infdis/jiae316
BibTeX
@article{Goswami2024,
author = {Goswami, Jaya and Baqui, Abdullah H and Doreski, Pablo A and Perez Marc, Gonzalo and Jimenez, Gilberto and Ahmed, Salahuddin and Zaman, Khalequz and Duncan, Christopher J A and Ujiie, Mugen and Rämet, Mika and Pérez-Breva, Lina and Lan, Lan and Du, Jiejun and Kapoor, Archana and Mehta, Shraddah and Tomassini, Joanne E and Huang, Wenmei and Zhou, Honghong and Stoszek, Sonia K and Priddy, Frances and Lin, Nina and Le Cam, Nancy and Shaw, Christine A and Slobod, Karen and Wilson, Eleanor and Miller, Jacqueline M and Das, Rituparna},
title = {Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {230},
number = {5},
pages = {e996--e1006},
doi = {10.1093/infdis/jiae316}
}
EUVIMED